Anordrin Eliminates Tamoxifen Side Effects without Changing Its Antitumor Activity.

ABSTRACT: Tamoxifen is administered for estrogen receptor positive (ER⁺) breast cancers, but it can induce uterine endometrial cancer and non-alcoholic fatty liver disease (NAFLD). Importantly, ten years of tamoxifen treatment has greater protective effect against ER⁺ breast cancer than five years of such treatment. Tamoxifen was also approved by the FDA as a chemopreventive agent for those deemed at high risk for the development of breast cancer. The side effects are of substantial concern because of these extended methods of tamoxifen administration. In this study, we found that anordrin, marketed as an antifertility medicine in China, inhibited tamoxifen-induced endometrial epithelial cell mitosis and NAFLD in mouse uterus and liver as an anti-estrogenic and estrogenic agent

SUBMITTER: Gu W 

PROVIDER: S-EPMC5339706 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature